Systemic Juvenile Idiopathic Arthritis
Immunology·MeSH: Arthritis, Juvenile
Prevalence
75.0 / 100K
3 drugs in development·3 companies·2 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| tofidence | BIOGEN INC. (BIIB) |
Phase 3(1)
| Drug | Company |
|---|---|
| Tocilizumab | ELI LILLY & Co (LLY) |
Phase 2(1)
Compare drugs
Frequently asked questions
How many drugs are in development for Systemic Juvenile Idiopathic Arthritis?
BioSniper tracks 3 drugs in development for Systemic Juvenile Idiopathic Arthritis across 3 companies.
How many clinical trials target Systemic Juvenile Idiopathic Arthritis?
There are 2 clinical trials targeting Systemic Juvenile Idiopathic Arthritis tracked by BioSniper.
What is the prevalence of Systemic Juvenile Idiopathic Arthritis?
The estimated prevalence of Systemic Juvenile Idiopathic Arthritis is approximately 75.0 per 100,000 population.
Deep-dive into Systemic Juvenile Idiopathic Arthritis
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis